Selective inhibitor of c-Jun N-terminal kinase (JNK) (IC50= 0.7μM). Inhibits the protein-protein interaction between JNK and JIP (IC50= 239 nM). Displays selectivity over p38 MAPK and Akt. Restores insulin sensitivity in a mouse model of type-2 diabetes.
Storage Temp
Protected from light,Store at -20°C,Argon charged
Shipped In
Ice chest + Ice pads
Grade
Moligand™
Action Type
INHIBITOR
Mechanism of action
Inhibitor of mitogen-activated protein kinase 8
Product Description
Product description：
SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. SU3327 also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. SU3327 shows less active against p38α and Akt kinase.
Associated Targets(Human)
MAPK8TchemMitogen-activated protein kinase 8 (0 Activities)
1.De SK, Stebbins JL, Chen LH, Riel-Mehan M, Machleidt T, Dahl R, Yuan H, Emdadi A, Barile E, Chen V et al.. (2009) Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase.. J Med Chem, 52 (7):(1943-52). [PMID:19271755][10.1021/op500134e]
2.Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, MacNair CR, French S, Carfrae LA, Bloom-Ackerman Z et al.. (2020) A Deep Learning Approach to Antibiotic Discovery.. Cell, 180 (4):(688-702.e13). [PMID:32084340][10.1021/op500134e]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
C2321769